Original Article
Brief Report
Neonatal Diabetes Mellitus Due to Complete Glucokinase Deficiency
N Engl J Med 2001; 344:1588-1592May 24, 2001
- Article
Diabetes mellitus is a heterogeneous disorder that can occur at any age.1 Neonatal diabetes mellitus, defined as insulin-requiring hyperglycemia within the first month of life, is a rare disorder that is usually associated with intrauterine growth retardation.2 Like diabetes in general, neonatal diabetes is heterogeneous and can be either transient or permanent. Transient neonatal diabetes is associated with abnormalities of chromosome 6,2,3 whereas mutations in insulin promoter factor 1 result in pancreatic agenesis and permanent neonatal diabetes.4 We describe two patients in whom complete deficiency of the glycolytic enzyme glucokinase, a key regulator of glucose metabolism in pancreatic beta cells that couples extracellular glucose to insulin secretion, caused permanent neonatal diabetes.5
Case Reports
Subject 1
A baby girl of Norwegian ancestry was delivered by cesarean section at 36 weeks' gestation (birth weight, 1670 g; length, 42 cm) because of poor fetal growth (Subject III-7 in Family 1 in Figure 1Figure 1
Pedigree of Family 1.).6 Her parents were first cousins, and both had glucose intolerance. In addition to being small for gestational age (less than the 3rd percentile), the infant had total situs inversus. On the first day of life, her blood glucose concentration was 145 mg per deciliter (8.1 mmol per liter), and on day 2 it was 300 mg per deciliter (17 mmol per liter), at which time treatment with insulin was started. The initial insulin requirement was 0.75 U per kilogram of body weight per day. Blood glucose control was difficult to achieve, and there were large variations in blood glucose concentrations (range, 35 to 630 mg per deciliter [2 to 35 mmol per liter]), but no ketosis. Tests for antibodies against insulin, glutamic acid decarboxylase, and protein tyrosine phosphatase–like molecule IA-2 (a major target antigen of cytoplasmic islet-cell antibodies) were negative. Basal and glucagon-stimulated serum C-peptide concentrations were nearly undetectable on several occasions. Plasma glucagon concentrations were within the normal range. The girl had no digestive problems.When the girl was five years old, epilepsy developed, probably as a sequela of a neonatal brain abscess, and she subsequently had mild learning and behavioral difficulties. Her motor development was normal. At the age of 15 years, the glycemic response to glucagon was normal. Her sister (Subject III-6 in Figure 1) presented with typical type 1 diabetes at the age of seven years. Her mother (Subject II-7 in Figure 1) was given a diagnosis of gestational diabetes at the age of 25 years. Her father (Subject II-6 in Figure 1) had impaired fasting glycemia that was treated with diet.
Subject 2
An eight-year-old girl of Italian ancestry (Subject III-1 in Family 2 in Figure 2Figure 2
Pedigree of Family 2.) had had hyperglycemia (blood glucose, 715 mg per deciliter [40 mmol per liter]) and marked growth retardation when she was born at 38 weeks' gestation (birth weight, 1650 g — less than the 3rd percentile). She had been treated with insulin since birth, initially with a dose of 2 U per kilogram per day and currently with a dose of 1.4 U per kilogram per day. No diabetes-related antibodies (i.e., against insulin or glutamic acid decarboxylase) were detected. Basal serum C-peptide concentrations were low at birth, declined further with age, and did not increase in response to glucagon. The girl had no evidence of diabetic complications. Her mother had impaired fasting glycemia, and her father had impaired glucose tolerance.Methods
The studies were approved by the ethics committees of each institution and performed according to the Declaration of Helsinki. Written informed consent was obtained from all subjects or their parents.
Molecular Genetic Studies
The exons, flanking introns, and promoter regions of the genes encoding hepatocyte nuclear factors 1α and 4α, insulin promoter factor 1, the NK-2 (drosophila) homeobox homologue 2, neurogenic differentiation factor 1–beta-cell E-box transactivator 2, and glucokinase were screened for mutations in members of Family 1 by direct sequencing of polymerase-chain-reaction (PCR) products. The genes for insulin promoter factor 1, NK-2 homeobox homologue 6, and glucokinase were screened for mutations in Subject III-1 in Family 2 by single-strand conformation polymorphism analysis (in the case of insulin promoter factor 1) or denaturing gradient gel electrophoresis (in the case of the other two genes) and sequencing of any PCR products with altered mobility.
Kinetic Analysis of Recombinant Wild-Type and Mutant Glucokinase
Wild-type and mutant forms of human beta-cell glucokinase were expressed in Escherichia coli, and the kinetic properties of the purified proteins in the presence of 2 mmol of dithiothreitol per liter of reaction mixture were determined as described previously.5 We used nonlinear kinetics according to the Hill equation. The relative-activity index was used as a measure of the glucose phosphorylation capacity of the enzyme.5 We normalized this relative-activity index to a value of 90 mg of basal glucose per deciliter (5 mmol per liter) with the use of the expression coefficient (5h × 2) ÷ (5h + S0.5 h), where h is the Hill coefficient (a coefficient that characterizes the sigmoidal glucose dependency of glucokinase) and S0.5 is the glucose concentration required for glucokinase activity to be half maximal in the presence of 5 mmol of ATP per liter in the case of wild-type glucokinase and 10 mmol of ATP per liter in the case of mutant glucokinase.
Mathematical Modeling
We used a minimal mathematical model to assess the effect of the substitution of lysine for methionine at position 210 (M210K) and the substitution of methionine for threonine at position 228 (T228M) of glucokinase, in both the homozygous and heterozygous state, on the glucose-stimulated rate of insulin secretion.5 We modified the model to account for the adaptation of both mutant proteins in the homozygous and the heterozygous state to a change in the basal glucose concentration by using the theoretically plausible expression (GB h × 2) ÷ (GB h + S0.5 h), where GB is the basal glucose concentration (i.e., 90 mg per deciliter [5 mmol per liter] for the controls, 125 mg per deciliter [7 mmol per liter] for persons with one affected allele, and 360 mg per deciliter [20 mmol per liter] for the patients with permanent neonatal diabetes mellitus).
Results
The clinical features of the two subjects with permanent neonatal diabetes (Subject III-7 in Family 1 and Subject III-1 in Family 2) suggested that they had a profound defect in beta-cell function. We therefore screened genes known to have a key role in the development and function of beta cells.7 In Subject III-7, we found no mutations in the genes encoding hepatocyte nuclear factor 1α or 4α, insulin promoter factor 1, neurogenic differentiation factor 1, or the NK-2 homeobox homologue 2. However, we did detect a novel missense mutation in exon 6 (codon 210 and complementary DNA nucleotide 629; from ATG to AAG; Genbank accession number, M88011) of the glucokinase gene that resulted in the substitution of lysine for methionine at amino acid residue 210 (M210K). The proband was homozygous for this mutation and her parents and sister were heterozygous. The mutation cosegregated with diabetes or hyperglycemia in other family members (Figure 1), and it was not found in 50 normal adults of Norwegian ancestry. These results suggested that in this family, a heterozygous M210K mutation caused the type 2 or glucokinase-related form of maturity-onset diabetes of the young and a homozygous M210K mutation caused permanent neonatal diabetes.
Subject III-1 in Family 2 was homozygous for a missense mutation in exon 7 (codon 228 and complementary DNA nucleotide 683; from ACG to ATG) of the glucokinase gene that resulted in the substitution of methionine for threonine at amino acid 228 (T228M). This mutation has been found previously in a family with glucokinase-related maturity-onset diabetes of the young.8 The girl's parents, although not known to be related, were heterozygous for this mutation (Figure 2). Preliminary molecular genetic studies suggest that there was a founder effect for this mutation in the parents.
Kinetic Analysis of Recombinant Glucokinase
We prepared recombinant wild-type glucokinase, glucokinase with the M210K mutation, and glucokinase with the T228M mutation in E. coli and compared the kinetic properties of the purified proteins (Figure 3Figure 3
Comparison of the Modeled Functional Properties of Wild-Type Glucokinase, Glucokinase with the M210K Mutation, and Glucokinase with the T228M Mutation.).5,9 The relative activity of the protein with the M210K mutation and the protein with the T228M mutation was 0.16 and 0.05 percent, respectively, of that of wild-type glucokinase. The turnover rate of the glucokinase with the M210K mutation was 32 percent of that of the wild-type enzyme, the S0.5 was increased by a factor of 5, and the ATP concentration required for glucokinase activity to be half maximal when glucose is in excess was increased by a factor of 3.9. The catalytic activity of the glucokinase with the T228M mutation was 0.008 percent of that of the wild-type enzyme, the S0.5 was 72 percent of that of the wild type, and the ATP concentration required for glucokinase activity to be half maximal when glucose is in excess was increased by a factor of 1.8. Thus, M210K and T228M are both inactivating mutations, suggesting that they are the cause of diabetes in Families 1 and 2, respectively.Mathematical Modeling and Pathophysiologic Implications
We used a modified minimal mathematical model5 to assess the effect of the M210K and T228M mutations on the glucose-stimulated rate of insulin secretion and glucose homeostasis (Figure 3). According to this model, 29 percent of the total glucokinase phosphorylating capacity of the beta cell is necessary to initiate insulin secretion in normal subjects, with the threshold defined as 90 mg per deciliter (5 mmol per liter). In the proband who was homozygous for the M210K mutation and the proband who was homozygous for the T228M mutation, this critical threshold is not reached even when the beta cell has adapted to a glucose concentration of 360 mg per deciliter. The parents of these subjects are heterozygous for either the M210K or the T228M mutation and had predicted thresholds for the glucose-stimulated rate of insulin secretion of about 125 mg per deciliter (7 mmol per liter), which is characteristic of patients with glucokinase-related maturity-onset diabetes of the young.
Discussion
We found that permanent neonatal diabetes can result from a complete deficiency of glucokinase activity. This finding is perhaps not surprising, considering the key role of glucokinase in the regulation of insulin secretion in humans with glucokinase-related maturity-onset diabetes of the young and in mice that lack one or both glucokinase alleles.3,9-12 Other mammalian hexokinases, such as hexokinase I, II, and III, which are characterized by a high affinity for glucose and unlike glucokinase are subject to feedback control, are no substitute for glucokinase, primarily because they are kinetically unsuited to serve as a glucose sensor for pancreatic beta cells.13 In contrast to patients with glucokinase-related maturity-onset diabetes of the young, who have a partial deficiency of glucokinase resulting in mild fasting hyperglycemia, our two subjects with permanent neonatal diabetes as a result of a complete deficiency of glucokinase had severe hyperglycemia and required insulin treatment soon after birth. In this regard, mice lacking glucokinase have growth retardation and hyperglycemia at birth and die soon thereafter. These mice also have hypertriglyceridemia, hepatic steatosis, and reduced stores of hepatic glycogen, abnormalities that were not present in the two subjects we studied. Subject III-7 in Family 1 had no obvious defect of hepatic glycogen storage and had a normal glycemic response to the administration of glucagon, a measure of the ability of the liver to store glycogen and to mobilize glucose.
The total absence of basal insulin release in our subjects with glucokinase-related permanent neonatal diabetes is unexplained. Why does basal insulin release, which normally contributes as much as half of the daily insulin output, cease even though it could be stimulated by other fuels (e.g., amino acids and fatty acids) and potentiated by hormones and neurotransmitters (e.g., glucagon-like peptide 1, gastric inhibitory peptide, and acetylcholine)?13 Systematic studies of the insulin secretory response in the two subjects may provide a better understanding of the role of glucose and other secretagogues in the regulation of insulin secretion.
The molecular basis for the situs inversus in Subject III-7 in Family 1 is unknown. The absence of situs inversus in Subject III-1 in Family 2 and in glucokinase-deficient mice suggests that it is not a consequence of glucokinase deficiency. Genetic factors have a role in determining left–right asymmetry,14 and Subject III-7 in Family 1 may have a mutation in a gene involved in this process.
Neonatal diabetes is a rare disorder with an estimated incidence of 1 in 400,000 live births.2 Although the true prevalence of glucokinase mutations is unknown, glucokinase-related maturity-onset diabetes of the young appears to be relatively common and underdiagnosed, because the majority of carriers do not have clinical diabetes.15 The frequency of glucokinase mutations may also be higher in some populations because of a founder effect.16 Thus, complete glucokinase deficiency could be the cause of a substantial proportion of cases of permanent neonatal diabetes. Mutations in this gene should be sought in infants with neonatal diabetes, especially if some first-degree relatives have glucose intolerance.
Supported by grants from the Norwegian Research Council, the Norwegian Diabetes Association, the Novo Nordic Foundation, the Unger-Vetlesen Charitable Fund, the U.S. Norway Fulbright Foundation (to Dr. Njølstad), the Public Health Service (DK-20595 and DK-44840, to Dr. Bell; DK-19525 and DK-22122, to Dr. Matschinsky; and DK-42502 and DK-42612, to Dr. Magnuson), and the Telethon Foundation (E.098 and E.0946, to Dr. Barbetti); by a gift from the Blum-Kovler Foundation; and by the Howard Hughes Medical Institute.
We are indebted to the members of Families 1 and 2 for their participation in the study, and to Ms. L. Grevle and Ms. I. Carbone for their expert technical assistance.
Source Information
From the Howard Hughes Medical Institute and the Departments of Biochemistry and Molecular Biology, Medicine, and Human Genetics, University of Chicago, Chicago (P.R.N., G.I.B.); the Department of Pediatrics (P.R.N., O.S.) and the Center for Medical Genetics and Molecular Medicine (L.B., A.M.), Haukeland University Hospital, University of Bergen, Bergen, Norway; the Department of Biochemistry and Biophysics and the Diabetes Research Center, University of Pennsylvania School of Medicine, Philadelphia (A.C.-M., F.M.M.); the San Raffaele Scientific Institute, Milan, Italy (O.M., F.B.); the Institute of Immunology, National Hospital, Oslo, Norway (D.E.U.); and the Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville (C.S., M.A.M.).
Address reprint requests to Dr. Njølstad at the Department of Pediatrics, Haukeland University Hospital, N-5021 Bergen, Norway, or at pal.njolstad@pedi.uib.no.
- References
References
1
Alberti KGM ,Zimmet PZ . Definition, diagnosis and classification of diabetes mellitus and its complications. 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553
CrossRef | Web of Science | Medline2
Shield JP . Neonatal diabetes: new insights into aetiology and implications. Horm Res 2000;53:Suppl 1:7-11
CrossRef | Web of Science | Medline3
Temple IK ,Gardner RJ ,Mackay DJ ,Barber JC ,Robinson DO ,Shield JP . Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes 2000;49:1359-1366
CrossRef | Web of Science | Medline4
Stoffers DA ,Zinkin NT ,Stanojevic V ,Clarke WL ,Habener JF . Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997;15:106-110
CrossRef | Web of Science | Medline5
Davis EA ,Cuesta-Munoz A ,Raoul M , et al. Mutants of glucokinase cause hypoglycaemia and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia 1999;42:1175-1186
CrossRef | Web of Science | Medline6
Sovik O ,Alsaker T ,Markestad T ,Myking O . Congenital diabetes mellitus: case report. Acta Endocrinol Suppl (Copenh) 1988;289:32-32 abstract.7
St Onge L ,Wehr R ,Gruss P . Pancreas development and diabetes. Curr Opin Genet Dev 1999;9:295-300
CrossRef | Web of Science | Medline8
Velho G ,Blanche H ,Vaxillaire M , et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997;40:217-224
CrossRef | Web of Science | Medline9
Mahalingam B ,Cuesta-Munoz A ,Davis EA ,Matschinsky FM ,Harrison RW ,Weber IT . Structural model of human glucokinase in complex with glucose and ATP: implications for the mutants that cause hypo- and hyperglycemia. Diabetes 1999;48:1698-1705
CrossRef | Web of Science | Medline10
Grupe A ,Hultgren B ,Ryan A ,Ma YH ,Bauer M ,Stewart TA . Transgenic knockouts reveal a critical requirement for pancreatic β-cell glucokinase in maintaining glucose homeostasis. Cell 1995;83:69-78
CrossRef | Web of Science | Medline11
Terauchi Y ,Kubota N ,Tamemoto H , et al. Insulin effect during embryogenesis determines fetal growth: a possible molecular link between birth weight and susceptibility to type 2 diabetes. Diabetes 2000;49:82-86
CrossRef | Web of Science | Medline12
Hattersley AT ,Beards F ,Ballantyne E ,Appleton M ,Harvey R ,Ellard S . Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet 1998;19:268-270
CrossRef | Web of Science | Medline13
Matschinsky FM ,Sweet IR . Annotated questions and answers about glucose metabolism and insulin secretion of β-cells. Diabetes Rev 1996;4:130-14414
Capdevila J ,Vogan KJ ,Tabin CJ ,Izpisua Belmonte JE . Mechanisms of left-right determination in vertebrates. Cell 2000;101:9-21
CrossRef | Web of Science | Medline15
Froguel P ,Zouali H ,Vionnet N , et al. Familial hyperglycemia due to mutations in glucokinase: definition of a subtype of diabetes mellitus. N Engl J Med 1993;328:697-702
Full Text | Web of Science | Medline16
Saker PJ ,Hattersley AT ,Barrow B , et al. High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population. Diabetologia 1996;39:1325-1328
CrossRef | Web of Science | Medline
- Citing Articles (92)
Citing Articles
1
Vandana Jain, Ming Chen,, Ram K. Menon. 2012. Disorders of Carbohydrate Metabolism. , 1320-1329.
CrossRef2
Siri Atma W. Greeley, Rochelle N. Naylor, Louis H. Philipson, Graeme I. Bell. (2011) Neonatal Diabetes: An Expanding List of Genes Allows for Improved Diagnosis and Treatment. Current Diabetes Reports 11:6, 519-532
CrossRef3
Beate Karges, Thomas Meissner, Andrea Icks, Thomas Kapellen, Reinhard W. Holl. (2011) Management of diabetes mellitus in infants. Nature Reviews Endocrinology
CrossRef4
K. Horvatovich, S. Bokor, N. Polgar, P. Kisfali, F. Hadarits, L. Jaromi, V. Csongei, J. Repasy, D. Molnar, B. Melegh. (2011) Functional glucokinase regulator gene variants have inverse effects on triglyceride and glucose levels, and decrease the risk of obesity in children. Diabetes & Metabolism 37:5, 432-439
CrossRef5
Mioara Larion, Brian G. Miller. (2011) Homotropic Allosteric Regulation in Monomeric Mammalian Glucokinase. Archives of Biochemistry and Biophysics
CrossRef6
Yael Gozlan, Ariel Tenenbaum, Shlomit Shalitin, Yael Lebenthal, Tal Oron, Ohad Cohen, Moshe Phillip, Galia Gat-Yablonski. (2011) The glucokinase mutation p.T206P is common among MODY patients of Jewish Ashkenazi descent. Pediatric Diabetesno-no
CrossRef7
Amnon Zung, Erwin Petek, Bruria Ben-Zeev, Thomas Schwarzbraun, Sagi Josefsberg Ben-Yehoshua. (2011) MODY type 2 in Greig cephalopolysyndactyly syndrome (GCPS) as part of a contiguous gene deletion syndrome. American Journal of Medical Genetics Part A 155:10, 2469-2472
CrossRef8
Maciej Borowiec, Malgorzata Mysliwiec, Wojciech Fendler, Karolina Antosik, Agnieszka Brandt, Maciej Malecki, Wojciech Mlynarski. (2011) Phenotype variability and neonatal diabetes in a large family with heterozygous mutation of the glucokinase gene. Acta Diabetologica 48:3, 203-208
CrossRef9
, L. Russo, D. Iafusco, S. Brescianini, V. Nocerino, C. Bizzarri, S. Toni, F. Cerutti, C. Monciotti, R. Pesavento, L. Iughetti, L. Bernardini, R. Bonfanti, L. Gargantini, M. Vanelli, L. Aguilar-Bryan, M. A. Stazi, V. Grasso, C. Colombo, F. Barbetti. (2011) Permanent diabetes during the first year of life: multiple gene screening in 54 patients. Diabetologia 54:7, 1693-1701
CrossRef10
Yi Quan, Andrew Barszczyk, Zhong-ping Feng, Hong-shuo Sun. (2011) Current understanding of KATP channels in neonatal diseases: focus on insulin secretion disorders. Acta Pharmacologica Sinica 32:6, 765-780
CrossRef11
Zehra Aycan, Semra Çetinkaya, Şerife Suna Oğuz, Serdar Ceylaner. (2011) A new variant of a known mutation in two siblings with permanent neonatal diabetes mellitus. Journal of Pediatric Endocrinology and Metabolism 24:5-6, 373-375
CrossRef12
Kate Bennett, Chela James, Angham Mutair, Hala Al-Shaikh, Aisha Sinani, Khalid Hussain. (2011) Four novel cases of permanent neonatal diabetes mellitus caused by homozygous mutations in the glucokinase gene. Pediatric Diabetes 12:3pt1, 192-196
CrossRef13
Janne Molnes, Knut Teigen, Ingvild Aukrust, Lise Bjørkhaug, Oddmund Søvik, Torgeir Flatmark, Pål Rasmus Njølstad. (2011) Binding of ATP at the active site of human pancreatic glucokinase - nucleotide-induced conformational changes with possible implications for its kinetic cooperativity. FEBS Journalno-no
CrossRef14
Masahiro Nishi, Kishio Nanjo. (2011) Insulin gene mutations and diabetes. Journal of Diabetes Investigation 2:2, 92-100
CrossRef15
Oscar Rubio-Cabezas, Tomasz Klupa, Maciej T. Malecki, . (2011) Permanent neonatal diabetes mellitus - the importance of diabetes differential diagnosis in neonates and infants. European Journal of Clinical Investigation 41:3, 323-333
CrossRef16
Esther J. Pearl, Zeina Jarikji, Marko E. Horb. (2011) Functional analysis of Rfx6 and mutant variants associated with neonatal diabetes. Developmental Biology 351:1, 135-145
CrossRef17
Yunfeng Shen, Mengyin Cai, Hua Liang, Hongwei Wang, Jianping Weng. (2011) Insight into the biochemical characteristics of a novel glucokinase gene mutation. Human Genetics 129:3, 231-238
CrossRef18
Walter Bonfig, Sandra Hermanns, Katharina Warncke, Gabriele Eder, Ilse Engelsberger, Stefan Burdach, Annette Gabriele Ziegler, Peter Lohse. (2011) GCK-MODY (MODY 2) Caused by a Novel p.Phe330Ser Mutation. ISRN Pediatrics 2011, 1-5
CrossRef19
N. Bouhours-Nouet, R. Coutant. (2011) Aspectos clínicos y diagnósticos de la diabetes infantil. EMC - Pediatría 46:4, 1-20
CrossRef20
Khalid Hussain. (2010) Mutations in pancreatic ß-cell Glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus. Reviews in Endocrine and Metabolic Disorders 11:3, 179-183
CrossRef21
Sarah E. Flanagan, Ann-Marie Patch, Sian Ellard. (2010) Using SIFT and PolyPhen to Predict Loss-of-Function and Gain-of-Function Mutations. Genetic Testing and Molecular Biomarkers 14:4, 533-537
CrossRef22
Siri Atma W. Greeley, Susan E. Tucker, Rochelle N. Naylor, Graeme I. Bell, Louis H. Philipson. (2010) Neonatal diabetes mellitus: A model for personalized medicine. Trends in Endocrinology & Metabolism 21:8, 464-472
CrossRef23
R. Gianani, M. Campbell-Thompson, S. A. Sarkar, C. Wasserfall, A. Pugliese, J. M. Solis, S. C. Kent, B. J. Hering, E. West, A. Steck, S. Bonner-Weir, M. A. Atkinson, K. Coppieters, M. Herrath, G. S. Eisenbarth. (2010) Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 53:4, 690-698
CrossRef24
Kristen D. McKnight, Pei Wang, Seung K. Kim. (2010) Deconstructing Pancreas Development to Reconstruct Human Islets from Pluripotent Stem Cells. Cell Stem Cell 6:4, 300-308
CrossRef25
Kathryn Beardsall, Carlo Acerini, David B Dunger. (2010) Physiological and clinical role of insulin in the neonate. Expert Review of Endocrinology & Metabolism 5:2, 197-207
CrossRef26
Barbara Wiedemann, Edith Schober, Thomas Waldhoer, Julia Koehle, Sarah E Flanagan, Deborah JG Mackay, Elisabeth Steichen, Dagmar Meraner, Lothar-Bernd Zimmerhackl, Andrew T Hattersley, Sian Ellard, Sabine Hofer. (2010) Incidence of neonatal diabetes in Austria-calculation based on the Austrian Diabetes Register. Pediatric Diabetes 11:1, 18-23
CrossRef27
M. Balasubramanian, J.P.H. Shield, C.L. Acerini, J. Walker, S. Ellard, M. Marchand, M. Polak, M. Vaxillaire, J.A. Crolla, D.J. Bunyan, D.J.G. Mackay, I.K. Temple. (2010) Pancreatic hypoplasia presenting with neonatal diabetes mellitus in association with congenital heart defect and developmental delay. American Journal of Medical Genetics Part A 152A:2, 340-346
CrossRef28
Dana Martinovici, Valérie Ransy, Serge Vanden Eijnden, Céline Ridremont, Anne Pardou, Marie Cassart, Freddy Avni, Catherine Donner, Pierre Lingier, Anne Mathieu, Béatrice Gulbis, Véronique De Brouckère, Miriam Cnop, Marc Abramowicz, Julie Désir. (2010) Neonatal hemochromatosis and Martinez-Frias syndrome of intestinal atresia and diabetes mellitus in a consanguineous newborn. European Journal of Medical Genetics 53:1, 25-28
CrossRef29
Maria Sara Remedi, Colin G. Nichols. (2009) Hyperinsulinism and Diabetes: Genetic Dissection of β Cell Metabolism-Excitation Coupling in Mice. Cell Metabolism 10:6, 442-453
CrossRef30
Inas H Thomas, Natinder K Saini, Amita Adhikari, Joyce M Lee, Josephine Z Kasa-vubu, Delia M Vazquez, Ram K Menon, Ming Chen, Stefan S Fajans. (2009) Neonatal diabetes mellitus with pancreatic agenesis in an infant with homozygous IPF-1 Pro63fsX60 mutation. Pediatric Diabetes 10:7, 492-496
CrossRef31
Kara K. Osbak, Kevin Colclough, Cecile Saint-Martin, Nicola L. Beer, Christine Bellanné-Chantelot, Sian Ellard, Anna L. Gloyn. (2009) Update on mutations in glucokinase ( GCK ), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Human Mutation 30:11, 1512-1526
CrossRef32
A. L. Gloyn. (2009) RD Lawrence Lecture 2009 Old genes, new tricks: learning about blood glucose regulation from naturally occurring genetic variation in humans. Diabetic Medicine 26:11, 1083-1089
CrossRef33
C. M. Batra, Nomeeta Gupta, Gurdeep Atwal, Vimal Gupta. (2009) Transient neonatal diabetes due to activating mutation in the ABCC8 gene encoding SUR1. The Indian Journal of Pediatrics 76:11, 1169-1172
CrossRef34
Maria E. Craig, Andrew Hattersley, Kim C. Donaghue. (2009) Definition, epidemiology and classification of diabetes in children and adolescents. Pediatric Diabetes 10, 3-12
CrossRef35
Andrew Hattersley, Jan Bruining, Julian Shield, Pal Njolstad, Kim C Donaghue. (2009) The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric Diabetes 10, 33-42
CrossRef36
Jesús Solera, Pedro Arias, Cintia Amiñoso, Isabel González-Casado, Pilar Garre, Lucrecia Herranz, Africa Villarroel, Marta Cruz, Mercedes Jáñez, Luís Felipe Pallardo, Ricardo Gracia. (2009) Identification of eight new mutations in the GCK gene by DHPLC screening in a Spanish population. Diabetes Research and Clinical Practice 85:1, 20-23
CrossRef37
Q. Qi, Y. Wu, H. Li, R. J. F. Loos, F. B. Hu, L. Sun, L. Lu, A. Pan, C. Liu, H. Wu, L. Chen, Z. Yu, X. Lin. (2009) Association of GCKR rs780094, alone or in combination with GCK rs1799884, with type 2 diabetes and related traits in a Han Chinese population. Diabetologia 52:5, 834-843
CrossRef38
Franz M. Matschinsky. (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nature Reviews Drug Discovery 8:5, 399-416
CrossRef39
Sarah E. Flanagan, S
verine Clauin, Christine Bellann
CrossRef40
Maciej T. Malecki, Wojciech Mlynarski, Jan Skupien. (2008) Can geneticists help clinicians to understand and treat non-autoimmune diabetes?. Diabetes Research and Clinical Practice 82, S83-S93
CrossRef41
Julie Støy, Siri Atma W Greeley, Veronica P Paz, Honggang Ye, Ashley N Pastore, Kinga B Skowron, Rebecca B Lipton, Fran R Cogen, Graeme I Bell, Louis H Philipson, . (2008) Diagnosis and treatment of neonatal diabetes: an United States experience†. Pediatric Diabetes 9:5, 450-459
CrossRef42
Jørn V Sagen, Lise Bjørkhaug, Janne Molnes, Helge Raeder, Louise Grevle, Oddmund Søvik, Anders Molven, Pål R Njølstad. (2008) Diagnostic screening of MODY2/ GCK mutations in the Norwegian MODY Registry. Pediatric Diabetes 9:5, 442-449
CrossRef43
Thomas Waterfield, Anna L Gloyn. (2008) Monogenic β-cell dysfunction in children: clinical phenotypes, genetic etiology and mutational pathways. Pediatric Health 2:4, 517-532
CrossRef44
Maciej T. Malecki, Wojciech Mlynarski. (2008) Monogenic diabetes: implications for therapy of rare types of disease. Diabetes, Obesity and Metabolism 10:8, 607-616
CrossRef45
Doga Turkkahraman, Iffet Bircan, Nicholas D. Tribble, Sema Akçurin, Sian Ellard, Anna L. Gloyn. (2008) Permanent Neonatal Diabetes Mellitus Caused by a Novel Homozygous (T168A) Glucokinase (GCK) Mutation: Initial Response to Oral Sulphonylurea Therapy. The Journal of Pediatrics 153:1, 122-126
CrossRef46
Louise Chappell, Shaun Gorman, Fiona Campbell, Sian Ellard, Gillian Rice, Angus Dobbie, Yanick Crow. (2008) A further example of a distinctive autosomal recessive syndrome comprising neonatal diabetes mellitus, intestinal atresias and gall bladder agenesis. American Journal of Medical Genetics Part A 146A:13, 1713-1717
CrossRef47
O Rubio-Cabezas, F Díaz González, A Aragonés, J Argente, A Campos-Barros. (2008) Permanent neonatal diabetes caused by a homozygous nonsense mutation in the glucokinase gene. Pediatric Diabetes 9:3pt1, 245-249
CrossRef48
Carlo Colombo, Ottavia Porzio, Ming Liu, Ornella Massa, Mario Vasta, Silvana Salardi, Luciano Beccaria, Carla Monciotti, Sonia Toni, Oluf Pedersen, Torben Hansen, Luca Federici, Roberta Pesavento, Francesco Cadario, Giorgio Federici, Paolo Ghirri, Peter Arvan, Dario Iafusco, Fabrizio Barbetti. (2008) Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. Journal of Clinical Investigation
CrossRef49
Janne Molnes, Lise Bjørkhaug, Oddmund Søvik, Pål R. Njølstad, Torgeir Flatmark. (2008) Catalytic activation of human glucokinase by substrate binding – residue contacts involved in the binding of D-glucose to the super-open form and conformational transitions. FEBS Journal 275:10, 2467-2481
CrossRef50
Rinki Murphy, Sian Ellard, Andrew T Hattersley. (2008) Clinical implications of a molecular genetic classification of monogenic β-cell diabetes. Nature Clinical Practice Endocrinology & Metabolism 4:4, 200-213
CrossRef51
Isabelle Flechtner, Martine Vaxillaire, Hélène Cavé, Raphael Scharfmann, Philippe Froguel, Michel Polak. (2008) Neonatal hyperglycaemia and abnormal development of the pancreas. Best Practice & Research Clinical Endocrinology & Metabolism 22:1, 17-40
CrossRef52
MARK A. SPERLING, STUART A. WEINZIMER, WILLIAM V. TAMBORLANE. 2008. Diabetes Mellitus. , 374-421.
CrossRef53
T. Sparsø, G. Andersen, T. Nielsen, K. S. Burgdorf, A. P. Gjesing, A. L. Nielsen, A. Albrechtsen, S. S. Rasmussen, T. Jørgensen, K. Borch-Johnsen, A. Sandbæk, T. Lauritzen, S. Madsbad, T. Hansen, O. Pedersen. (2007) The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51:1, 70-75
CrossRef54
Peter L. Oliver, Emmanuelle Bitoun, Kay E. Davies. (2007) Comparative genetic analysis: the utility of mouse genetic systems for studying human monogenic disease. Mammalian Genome 18:6-7, 412-424
CrossRef55
Martijn van de Bunt, Anna L Gloyn. (2007) Monogenic disorders of the pancreatic β-cell: personalizing treatment for rare forms of diabetes and hypoglycemia. Personalized Medicine 4:3, 247-259
CrossRef56
Struan FA Grant, Hakon Hakonarson. (2007) Recent development in pharmacogenomics: from candidate genes to genome-wide association studies. Expert Review of Molecular Diagnostics 7:4, 371-393
CrossRef57
I. Rica, C. Luzuriaga, G. Pérez de Nanclares, I. Estalella, A. Aragonés, R. Barrio, J. R. Bilbao, C. Carlés, C. Fernández, J. M. Fernández, E. Fernández-Rebollo, E. Gastaldo, P Giralt, J. M. Gomez Vida, A. Gutiérrez, J. P. López Siguero, M. J. Martínez-Aedo, M. Muñoz, J. Prieto, J. Rodrigo, F. Vargas, L. Castano. (2007) The majority of cases of neonatal diabetes in Spain can be explained by known genetic abnormalities. Diabetic Medicine 24:7, 707-713
CrossRef58
Óscar Rubio Cabezas, Jesús Argente Oliver. (2007) Diabetes mellitus en la infancia: una enfermedad heterogénea. Medicina Clínica 128:16, 627-633
CrossRef59
David A. Cano, Matthias Hebrok, Martin Zenker. (2007) Pancreatic Development and Disease. Gastroenterology 132:2, 745-762
CrossRef60
Annabelle S. Slingerland. (2007) Monogenic diabetes in children and young adults: Challenges for researcher, clinician and patient. Reviews in Endocrine and Metabolic Disorders 7:3, 171-185
CrossRef61
Maria E Craig, Andrew Hattersley, Kim Donaghue. (2006) ISPAD Clinical Practice Consensus Guidelines 2006?2007 Definition, epidemiology and classification. Pediatric Diabetes 7:6, 343-351
CrossRef62
E. L. Edghill, C. Bingham, A. S. Slingerland, J. A. L. Minton, C. Noordam, S. Ellard, A. T. Hattersley. (2006) Hepatocyte nuclear factor-1 beta mutations cause neonatal diabetes and intrauterine growth retardation: support for a critical role of HNF-1? in human pancreatic development. Diabetic Medicine 23:12, 1301-1306
CrossRef63
I Flechtner, P De Lonlay, M Polak. (2006) Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel. Diabetes & Metabolism 32:6, 569-580
CrossRef64
Wei Zhang, Daorong Feng, Yulin Li, Kaori Iida, Barbara McGrath, Douglas R. Cavener. (2006) PERK EIF2AK3 control of pancreatic β cell differentiation and proliferation is required for postnatal glucose homeostasis. Cell Metabolism 4:6, 491-497
CrossRef65
Sarah L. Woolley, Shyam Saranga. (2006) Neonatal diabetes mellitus: a rare but important diagnosis in the critically ill infant. European Journal of Emergency Medicine 13:6, 349-351
CrossRef66
Andrew Hattersley, Jan Bruining, Julian Shield, Pal Njolstad, Kim Donaghue. (2006) ISPAD Clinical Practice Consensus Guidelines 2006?2007 The diagnosis and management of monogenic diabetes in children. Pediatric Diabetes 7:6, 352-360
CrossRef67
J. R. Porter, J. J. Rangasami, S. Ellard, A. L. Gloyn, B. M. Shields, J. Edwards, J. M. Anderson, N. J. Shaw, A. T. Hattersley, T. M. Frayling, M. Plunkett, T. G. Barrett. (2006) Asian MODY: are we missing an important diagnosis?. Diabetic Medicine 23:11, 1257-1260
CrossRef68
Anna L Gloyn, Sian Ellard. (2006) Defining the genetic aetiology of monogenic diabetes can improve treatment. Expert Opinion on Pharmacotherapy 7:13, 1759-1767
CrossRef69
Babenko, Andrey P., Polak, Michel, Cavé, Hélène, Busiah, Kanetee, Czernichow, Paul, Scharfmann, Raphael, Bryan, Joseph, Aguilar-Bryan, Lydia, Vaxillaire, Martine, Froguel, Philippe, . (2006) Activating Mutations in the ABCC8 Gene in Neonatal Diabetes Mellitus. New England Journal of Medicine 355:5, 456-466
Full Text70
Anna L. Gloyn, Juveria Siddiqui, Sian Ellard. (2006) Mutations in the genes encoding the pancreatic beta-cell K ATP channel subunits Kir6.2 ( KCNJ11 ) and SUR1 ( ABCC8 ) in diabetes mellitus and hyperinsulinism. Human Mutation 27:3, 220-231
CrossRef71
Tara Bharucha, Justin Brown, Ciara McDonnell, Robecca Gebert, Peter McDougall, Fergus Cameron, George Werther, Margaret Zacharin. (2005) Neonatal diabetes mellitus: Insulin pump as an alternative management strategy. Journal of Paediatrics and Child Health 41:9-10, 522-526
CrossRef72
N. Shehadeh, D. Bakri, P. R. Njolstad, R. Gershoni-Baruch. (2005) Clinical characteristics of mutation carriers in a large family with glucokinase diabetes (MODY2). Diabetic Medicine 22:8, 994-998
CrossRef73
Mark A Sperling. (2005) Neonatal diabetes mellitus: from understudy to center stage. Current Opinion in Pediatrics 17:4, 512-518
CrossRef74
Thomas Kietzmann, Goutham Kumar Ganjam. (2005) Glucokinase: old enzyme, new target. Expert Opinion on Therapeutic Patents 15:6, 705-713
CrossRef75
Khalid Hussain, Karen E Cosgrove. (2005) From congenital hyperinsulinism to diabetes mellitus: the role of pancreatic beta-cell KATP channels. Pediatric Diabetes 6:2, 103-113
CrossRef76
I. Barroso. (2005) Genetics of Type 2 diabetes. Diabetic Medicine 22:5, 517-535
CrossRef77
A. A. Toye, J. D. Lippiat, P. Proks, K. Shimomura, L. Bentley, A. Hugill, V. Mijat, M. Goldsworthy, L. Moir, A. Haynes, J. Quarterman, H. C. Freeman, F. M. Ashcroft, R. D. Cox. (2005) A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. Diabetologia 48:4, 675-686
CrossRef78
Charles A. Stanley, Eugenia K. Pallotto. 2005. Disorders of Carbohydrate Metabolism. , 1410-1422.
CrossRef79
Shigeru Suzuki, Tokuo Mukai, Kimiaki Uetake, Syun-ichi Sageshima, Kumihiro Matsuo, Osamu Ueda, Yoshiya Ito, Kenji Fujieda. (2005) Permanent Neonatal Diabetes Mellitus with Growth Disturbance, Developmental Delay, Epilepsy and Dysmorphic Features. Clinical Pediatric Endocrinology 14:Supplement24, S24_81-S24_84
CrossRef80
Jos?? Timsit, Christine Bellann??-Chantelot, Dani??le Dubois-Laforgue, Gilberto Velho. (2005) Diagnosis and Management of Maturity-Onset Diabetes of the Young. Treatments in Endocrinology 4:1, 9-18
CrossRef81
Ornella Massa, Dario Iafusco, Elena D'Amato, Anna L. Gloyn, Andrew T. Hattersley, Bruno Pasquino, Giorgio Tonini, Francesco Dammacco, Giorgio Zanette, Franco Meschi, Ottavia Porzio, Gianfranco Bottazzo, Antonino Crin
CrossRef82
Kupper A. Wintergerst, Susan Hargadon, Helen Y. Hsiang. (2004) Continuous subcutaneous insulin infusion in neonatal diabetes mellitus. Pediatric Diabetes 5:4, 202-206
CrossRef83
Gabrielle S Sellick, Karen T Barker, Irene Stolte-Dijkstra, Christina Fleischmann, Richard J Coleman, Christine Garrett, Anna L Gloyn, Emma L Edghill, Andrew T Hattersley, Peter K Wellauer, Graham Goodwin, Richard S Houlston. (2004) Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nature Genetics 36:12, 1301-1305
CrossRef84
Constantin Polychronakos. (2004) Early onset diabetes mellitus. Tip or iceberg?. Pediatric Diabetes 5:4, 171-173
CrossRef85
J. Mitchell, Z. Punthakee, B. Lo, C. Bernard, K. Chong, C. Newman, L. Cartier, V. Desilets, E. Cutz, I. L. Hansen, P. Riley, C. Polychronakos. (2004) Neonatal diabetes, with hypoplastic pancreas, intestinal atresia and gall bladder hypoplasia: search for the aetiology of a new autosomal recessive syndrome. Diabetologia 47:12, 2160-2167
CrossRef86
Gloyn, Anna L., Pearson, Ewan R., Antcliff, Jennifer F., Proks, Peter, Bruining, G. Jan, Slingerland, Annabelle S., Howard, Neville, Srinivasan, Shubha, Silva, José M.C.L., Molnes, Janne, Edghill, Emma L., Frayling, Timothy M., Temple, I. Karen, Mackay, Deborah, Shield, Julian P.H., Sumnik, Zdenek, van Rhijn, Adrian, Wales, Jerry K.H., Clark, Penelope, Gorman, Shaun, Aisenberg, Javier, Ellard, Sian, Njølstad, Pål R., Ashcroft, Frances M., Hattersley, Andrew T., . (2004) Activating Mutations in the Gene Encoding the ATP-Sensitive Potassium-Channel Subunit Kir6.2 and Permanent Neonatal Diabetes. New England Journal of Medicine 350:18, 1838-1849
Full Text87
Satoshi Ashizawa, F. Charles Brunicardi, Xiao-Ping Wang. (2004) PDX-1 and the Pancreas. Pancreas 28:2, 109-120
CrossRef88
Anna L. Gloyn. (2003) Glucokinase ( GCK ) mutations in hyper- and hypoglycemia: Maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Human Mutation 22:5, 353-362
CrossRef89
S. Loon, J. P. Winter, J. Lier, H. Cavé, M. Vroede. (2003) Een patiënt met voorbijgaande neonatale diabetes mellitus. Tijdschrift voor kindergeneeskunde 71:2, 237-240
CrossRef90
J. P. H. Shield, I. K. Temple. (2002) Neonatal diabetes mellitus. Pediatric Diabetes 3:2, 109-112
CrossRef91
David Q. Shih, Markus Stoffel. (2002) Molecular etiologies of mody and other early-onset forms of diabetes. Current Diabetes Reports 2:2, 125-134
CrossRef92
Fajans, Stefan S., Bell, Graeme I., Polonsky, Kenneth S., . (2001) Molecular Mechanisms and Clinical Pathophysiology of Maturity-Onset Diabetes of the Young. New England Journal of Medicine 345:13, 971-980
Full Text
